For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells.
The process is quick and effective, representing a pioneering contribution for applying direct reprogramming for inducing immunity. Importantly, the finding opens up the possibility of developing novel dendritic cell-based immunotherapies against cancer.
Our so-called dendritic cells function as the immune system’s sentinels. Their task is to scan our tissues for foreign particles, such as bacteria, viruses or cancer cells, and to devour them. They subsequently break down the particles into smaller pieces, known as antigens, and present them on the surface to the immune system’s killer cells (T-cells). In this way, the killer cells learn which infectious agents and cancer cells they are to search for and kill.
Due to these key features, dendritic cell-based strategies have been tested to treat cancer patients. However, cancer can affect the dendritic cells in such a way that they get lost or become dysfunctional. We therefore need to find new ways of generating dendritic cells for every patient. Now, for the first time, a research team in Lund has succeeded in obtaining dendritic cells by a process called direct reprogramming. They have identified three essential proteins (PU.1, IRF8 and BATF3) that are required and sufficient to change the identity of mouse cells to make them become dendritic cells instead. They have also confirmed that the same protein cocktail reprograms human skin-derived cells to dendritic cells. This study is now published and highlighted in the cover of the journal Science Immunology.
“From a tissue section taken from the skin, we can cultivate millions of cells and reprogram them to dendritic cells in a process that takes only nine days”, says Filipe Pereira, the leader of the research team that conducted the study.
“Our study has shown that reprogrammed cells have the ability to effectively capture and present antigens to killer cells in the same way as ‘natural’ dendritic cells.” The researchers can even direct the induced dendritic cells towards a particular target by presenting the right antigen to them in a test tube, before introducing the cells into the organism. This finding opens up future possibilities to develop new strategies for immunotherapy against solid tumours and blood cancers, beyond the treatments currently available.
“This represents an excellent opportunity to merge the fields of cellular reprogramming and cancer immunotherapy. Generating dendritic cells employing direct cell reprogramming is very attractive from a therapeutic perspective: our studies may be useful in the clinic for generation of patient-specific dendritic cells”, according to Filipe Pereira.
Cancer immunotherapy employs the cellular components of a persons’ immune system to fight cancer and it was awarded with the Nobel Prize in Physiology or Medicine this year. By using reprogrammed dendritic cells the probability of rejection by the organism is lower as these cells can be generated from the skin of each individual patient.
“Tumours often undergo a number of mutations, developing into a heterogeneous entity, which makes it more difficult for the immune system to identify them as a threat. In a more creative perspective, we now want to explore the process of dendritic cell reprogramming to develop a cancer gene therapy. We are aiming at injecting the three reprogramming proteins straight into the tumour forcing it to present their own tumour-specific antigens. This allows the activation of the killer cells against tumour cells and may lead to their elimination. We have named this concept TrojanDC in an analogy with Homero’s Trojan horse. The great potential of this technology for cancer treatment lead us to start a new company together with Lund University for the development of this concept into a product that hopefully will reach cancer patients one day”, says Filipe Pereira.
“Additionally, our studies open up the possibility of reprogramming other dendritic cell sub-types taking advantage of their distinct functional features. A better understanding of the mechanisms that determine the identity of immune sentinels and of how to use this knowledge to reprogram other cell types into dendritic cells could make these patient-specific cells useful in the clinic”, concludes Filipe Pereira.
Learn more: WATCH: A code for reprogramming immune sentinels
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- Week In Review: InnoCare Prices Hong Kong IPO To Raise $288 Millionon March 22, 2020 at 10:53 am
The company develops immunotherapies for cancer and autoimmune diseases. It has three molecules in clinical trials, including its lead product, a BTK inhibitor under NDA review in China for leukemia ...
- OncoSec Medical Incorporated to Present at the New York City based Investor Summit on March 25th-26thon March 20, 2020 at 5:13 pm
NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, ...
- Dragonfly Therapeutics Completes New Investment Roundon March 19, 2020 at 5:09 pm
A new round of investment will allow Dragonfly to further accelerate development of its novel innate immune system and Natural Killer cell-based immunotherapies into the clinic. WALTHAM, Mass., March ...
- Primmune Therapeutics Raises USD 7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseaseson March 18, 2020 at 11:36 pm
SAN DIEGO: Primmune Therapeutics announced that it has raised USD 7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7 ...
- A New Star in Treatment to Fight Canceron March 18, 2020 at 8:55 pm
ITRI’s work in the development of precision medicine has again garnered international accolades. After winning a 2019 R&D 100 Award, ITRI’s iKNOBEADS, the world’s only biomimetic knobby magnetic beads ...
- Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapieson March 17, 2020 at 6:17 am
HOUSTON, Texas & TUEBINGEN, Germany--(BUSINESS WIRE)--Immatics Biotechnologies GmbH (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of ...
- Cancer Immunotherapies Market By Current Industry Status,Growth Opportunities, Top Key Players, Target Audience And Forecast To 2026on March 12, 2020 at 2:44 am
A recent report provides crucial insights along with application based and forecast information in the Global Cancer Immunotherapies Market. The report provides a comprehensive analysis of key factors ...
- Scientists uncover a mechanism that could lead to new immunotherapies head and neck canceron March 10, 2020 at 8:21 am
Researchers at UC have discovered a previously unknown mechanism that could explain the reason behind decreased immune function in cancer patients and could be a new therapeutic target for ...
- Insights on Triple-Negative Breast Cancer - Approval and Subsequent Uptake of New Targeted Therapies and Immunotherapies Driving Growthon March 9, 2020 at 1:05 pm
/PRNewswire/ -- The "Disease Analysis: Triple-Negative Breast Cancer" report has been added to ResearchAndMarkets.com's offering. Latest Key ...
via Bing News